drugset
drugset / Trial / NCT05972278

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

NCT05972278 ↗

Phase 1 Active not recruiting 22 enrolled NewAmsterdam Pharma University of Pennsylvania · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).

Timeline

Start
2023-12-01
Primary completion
2024-09-26
Completion
2024-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Obicetrapib Small molecule 10 mg —

Indications

No indication recorded.